All In Biotech

Drug Trial Radar · NCT06603220

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Aug 14, 2024

Primary completion

May 8, 2025

Study completion May 8, 2025

Sponsor

Lead sponsor
Evommune, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

Conditions

  • Chronic Inducible Urticaria

Interventions

  • Oral EVO756 300 mg QDDrug

    Oral EVO756, 300 mg once daily

  • Oral EVO756 50 mg BIDDrug

    Oral EVO756 50 mg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Day 1 to Week 6

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama

  • California Allergy and Asthma Medical Group

    Los Angeles, California

  • Integrative Skin Science and Research

    Sacramento, California

  • West Dermatology Research Center

    San Diego, California

  • Advanced Clinical Research Institute

    Tampa, Florida

  • Aeroallergy Research Laboratories of Savannah, Inc.

    Savannah, Georgia

  • Treasure Valley Medical Research

    Boise, Idaho

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Southern Indiana Clinical Trials

    New Albany, Indiana

  • Indiana Clinical Trials Center, P.C.

    Plainfield, Indiana

  • DelRicht Research

    Baton Rouge, Louisiana

  • Chesapeake Clinical Research, Inc

    White Marsh, Maryland

  • OptiSkin Medical

    New York, New York

  • Red River Research Partners

    Fargo, North Dakota

  • Bexley Dermatology Research

    Bexley, Ohio

  • Allergy, Asthma, and Clinical Research Center

    Oklahoma City, Oklahoma

  • Allergy and Clinical Immunology Associates

    Pittsburgh, Pennsylvania

  • Austin Institute for Clinical Research

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.